Trovagene (TROV) Misses Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. SPY
7. CVS
8. UNH
9. ZETA
10. DAL

Go back to Trovagene (TROV) Misses Q4 EPS by 1c

Trovagene Announces Fourth Quarter and Year End 2015 Financial Results

March 10, 2016 4:14 PM EST

SAN DIEGO, March 10, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and year ended December 31, 2015.

"2015 was our coming out year, as the introduction of our liquid biopsy solution for cancer monitoring was met with great response by physicians," said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "In support of our commercial efforts, we are assembling a compendium of clinical data, published manuscripts, and case studies in real-world... More